{"transactions":[{"id":2393794,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":130391,"kind":"person","name":"Zawel Leigh","position":1,"cik":"0001837456","reported_name":"Zawel Leigh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-15T21:47:15.000Z","date":"2022-02-11","kind":"grant","acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the option vest over four years, with one forty-eighty (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date."}],"balance_after":65000,"derivative":{"exercise_price":13.6,"expiration_date":"2032-02-10","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0000899243-22-006417","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924322006417/doc4.xml","form_type":"4"}},{"id":2393793,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":130391,"kind":"person","name":"Zawel Leigh","position":1,"cik":"0001837456","reported_name":"Zawel Leigh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-02-15T21:47:15.000Z","date":"2022-02-11","kind":"grant","acquired":true,"shares":32500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares underlying the restricted stock unit vest over four years, with one forty-eighty (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date."}],"balance_after":69785,"source":{"system":"sec-edgar","filing":"0000899243-22-006417","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924322006417/doc4.xml","form_type":"4"}},{"id":2540177,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":130391,"kind":"person","name":"Zawel Leigh","position":1,"cik":"0001837456","reported_name":"Zawel Leigh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-10-18T20:15:20.000Z","date":"2021-10-15","kind":"sale","acquired":false,"shares":19574,"price":25,"value":489350.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 26, 2021."}],"balance_after":37285,"source":{"system":"sec-edgar","filing":"0000899243-21-040453","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924321040453/doc4.xml","form_type":"4"}},{"id":2544075,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":130391,"kind":"person","name":"Zawel Leigh","position":1,"cik":"0001837456","reported_name":"Zawel Leigh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-10-12T20:30:32.000Z","date":"2021-10-07","kind":"sale","acquired":false,"shares":1079,"price":25,"value":26975.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 26, 2021."}],"balance_after":56859,"source":{"system":"sec-edgar","filing":"0000899243-21-039858","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924321039858/doc4.xml","form_type":"4"}},{"id":2562595,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":130391,"kind":"person","name":"Zawel Leigh","position":1,"cik":"0001837456","reported_name":"Zawel Leigh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-09-21T20:30:25.000Z","date":"2021-09-20","kind":"sale","acquired":false,"shares":7468,"price":25.16,"value":187894.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 26, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.46. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":57938,"source":{"system":"sec-edgar","filing":"0000899243-21-036781","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924321036781/doc4.xml","form_type":"4"}},{"id":2575531,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":130391,"kind":"person","name":"Zawel Leigh","position":1,"cik":"0001837456","reported_name":"Zawel Leigh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-09-08T20:15:19.000Z","date":"2021-09-07","kind":"sale","acquired":false,"shares":28118,"price":28.95,"value":814016.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 26, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.62 to $29.29. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":65406,"source":{"system":"sec-edgar","filing":"0000899243-21-035331","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924321035331/doc4.xml","form_type":"4"}},{"id":2589207,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":130391,"kind":"person","name":"Zawel Leigh","position":1,"cik":"0001837456","reported_name":"Zawel Leigh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-08-26T23:20:33.000Z","date":"2021-08-10","kind":"sale","acquired":false,"shares":1817,"price":28.49,"value":51766.33,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 26, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $28.07 to $28.74. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":121642,"source":{"system":"sec-edgar","filing":"0000899243-21-034314","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924321034314/doc4a.xml","form_type":"4/A","original_submission_date":"2021-08-11"}},{"id":2589206,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":130391,"kind":"person","name":"Zawel Leigh","position":1,"cik":"0001837456","reported_name":"Zawel Leigh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-08-26T23:20:33.000Z","date":"2021-08-10","kind":"sale","acquired":false,"shares":3191,"price":27.34,"value":87241.94,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 26, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $26.95 to $27.71. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":123459,"source":{"system":"sec-edgar","filing":"0000899243-21-034314","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924321034314/doc4a.xml","form_type":"4/A","original_submission_date":"2021-08-11"}},{"id":2589205,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":130391,"kind":"person","name":"Zawel Leigh","position":1,"cik":"0001837456","reported_name":"Zawel Leigh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-08-26T23:20:33.000Z","date":"2021-08-10","kind":"sale","acquired":false,"shares":1906,"price":26.5,"value":50509.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 26, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $25.95 to $26.91. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":126650,"source":{"system":"sec-edgar","filing":"0000899243-21-034314","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924321034314/doc4a.xml","form_type":"4/A","original_submission_date":"2021-08-11"}},{"id":2589204,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":130391,"kind":"person","name":"Zawel Leigh","position":1,"cik":"0001837456","reported_name":"Zawel Leigh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-08-26T23:20:33.000Z","date":"2021-08-09","kind":"sale","acquired":false,"shares":1700,"price":27.11,"value":46087.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 26, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $26.98 to $27.40. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":128556,"source":{"system":"sec-edgar","filing":"0000899243-21-034314","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924321034314/doc4a.xml","form_type":"4/A","original_submission_date":"2021-08-11"}},{"id":2589203,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":130391,"kind":"person","name":"Zawel Leigh","position":1,"cik":"0001837456","reported_name":"Zawel Leigh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-08-26T23:20:33.000Z","date":"2021-08-09","kind":"sale","acquired":false,"shares":19504,"price":26.52,"value":517246.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 26, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $25.98 to $26.90. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":130256,"source":{"system":"sec-edgar","filing":"0000899243-21-034314","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924321034314/doc4a.xml","form_type":"4/A","original_submission_date":"2021-08-11"}},{"id":2589198,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":130391,"kind":"person","name":"Zawel Leigh","position":1,"cik":"0001837456","reported_name":"Zawel Leigh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-08-26T23:14:45.000Z","date":"2021-08-23","kind":"sale","acquired":false,"shares":28118,"price":29,"value":815422.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 26, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.60 to $29.26. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":93524,"source":{"system":"sec-edgar","filing":"0000899243-21-034311","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924321034311/doc4a.xml","form_type":"4/A","original_submission_date":"2021-08-24"}},{"id":2591831,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":130391,"kind":"person","name":"Zawel Leigh","position":1,"cik":"0001837456","reported_name":"Zawel Leigh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-08-24T20:06:19.000Z","date":"2021-08-23","kind":"sale","acquired":false,"shares":28118,"price":29,"value":815422.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.60 to $29.26. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":93524,"source":{"system":"sec-edgar","filing":"0000899243-21-034027","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924321034027/doc4.xml","form_type":"4"}},{"id":2606372,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":130391,"kind":"person","name":"Zawel Leigh","position":1,"cik":"0001837456","reported_name":"Zawel Leigh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-08-11T20:15:39.000Z","date":"2021-08-10","kind":"sale","acquired":false,"shares":1817,"price":28.49,"value":51766.33,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $28.07 to $28.74. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":121642,"source":{"system":"sec-edgar","filing":"0000899243-21-032515","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924321032515/doc4.xml","form_type":"4"}},{"id":2606371,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":130391,"kind":"person","name":"Zawel Leigh","position":1,"cik":"0001837456","reported_name":"Zawel Leigh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-08-11T20:15:39.000Z","date":"2021-08-10","kind":"sale","acquired":false,"shares":3191,"price":27.34,"value":87241.94,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $26.95 to $27.71. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":123459,"source":{"system":"sec-edgar","filing":"0000899243-21-032515","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924321032515/doc4.xml","form_type":"4"}},{"id":2606370,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":130391,"kind":"person","name":"Zawel Leigh","position":1,"cik":"0001837456","reported_name":"Zawel Leigh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-08-11T20:15:39.000Z","date":"2021-08-10","kind":"sale","acquired":false,"shares":1906,"price":26.5,"value":50509.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $25.95 to $26.91. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":126650,"source":{"system":"sec-edgar","filing":"0000899243-21-032515","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924321032515/doc4.xml","form_type":"4"}},{"id":2606369,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":130391,"kind":"person","name":"Zawel Leigh","position":1,"cik":"0001837456","reported_name":"Zawel Leigh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-08-11T20:15:39.000Z","date":"2021-08-09","kind":"sale","acquired":false,"shares":1700,"price":27.11,"value":46087.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $26.98 to $27.40. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":128556,"source":{"system":"sec-edgar","filing":"0000899243-21-032515","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924321032515/doc4.xml","form_type":"4"}},{"id":2606368,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":130391,"kind":"person","name":"Zawel Leigh","position":1,"cik":"0001837456","reported_name":"Zawel Leigh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-08-11T20:15:39.000Z","date":"2021-08-09","kind":"sale","acquired":false,"shares":19504,"price":26.52,"value":517246.08,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $25.98 to $26.90. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":130256,"source":{"system":"sec-edgar","filing":"0000899243-21-032515","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924321032515/doc4.xml","form_type":"4"}},{"id":2910413,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":130391,"kind":"person","name":"Zawel Leigh","position":1,"cik":"0001837456","reported_name":"Zawel Leigh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-11T22:36:17.000Z","date":"2021-01-07","kind":"grant","acquired":true,"shares":56666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option represents a right to purchase a total of 56,666 shares of the Issuer's Common Stock, 25% of which will become fully vested and exercisable on January 7, 2022, with the remaining shares vesting in equal monthly installments over the following three years (36 months), subject to the reporting person's continued employment with the Issuer."}],"balance_after":56666,"derivative":{"exercise_price":21,"expiration_date":"2031-01-06","underlying":"Common Stock","underlying_shares":56666},"source":{"system":"sec-edgar","filing":"0000899243-21-001367","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1789972/000089924321001367/doc4.xml","form_type":"4"}}]}